San Francisco, 25
October 2018: The APAC radiopharmaceuticals/nuclear medicine market is expected to reach USD 2.9 billion by 2024,
according to the new report by Grand View Research, Inc. Radiopharmaceuticals
are widely used in the field of oncology, and cardiovascular diseases. Ongoing
research and studies demonstrating positive results is widening the scope of
radioisotope applications for the diagnosis and treatment of bone diseases,
respiratory diseases, thyroid-related diseases, and conditions of the digestive
tract. Along with these applications, the radioisotopes are largely used in
radiopharmacology to study drug movement in lab subjects.
Gamma emitter
Technetium-99m is the most commonly used radioisotope in radiopharmaceuticals.
Other widely used radioisotopes include Fluorine-18, Indium-111, and
Iodine-131. Numerous research studies are further expanding the application
areas of radiopharmaceuticals in diagnostics as well as in therapeutics.
Adoption of PET as a
diagnostic tool is rapidly increasing since it offers high accuracy over other
diagnostic techniques. The accuracy in the diagnosis has a direct impact on
decision-making and treatment monitoring process. PET is commonly integrated
with X-ray and computed tomography to increase the accuracy. The growing demand
for these diagnostic procedures is expected to fuel the market growth during
the forecast period.
Currently available
cancer treatment options, such as chemotherapy and radiation therapy, include
drugs and radiations, which are non-target specific. Thus, these therapies have
a major disadvantage of affecting the whole body or the organs surrounding the
target site. Radioisotopes have an advantage over these techniques since they
aid in targeting specifically the tumor without affecting the surrounding body
parts. Thus, benefits associated with these diagnostic and treatment procedures
is augmenting the demand for radiopharmaceuticals in disease treatment and
diagnosis.
Access Research Report
of APAC
Radiopharmaceuticals Market @ www.grandviewresearch.com/industry-analysis/asia-pacific-radiopharmaceuticals-market
Further key findings from the study suggest:
· The buyers of radiopharmaceutical include
hospitals, physicians, diagnostic laboratories, research institutes and others.
Hospitals form the biggest buyer groups owing to their high patient turnover
and greater financing capabilities.
· Therapeutic products such as Alpha
Emitters, Beta Emitters and Brachytherapy are anticipated to exhibit lucrative
growth. Emergence of new treatment options for thyroid and other diseases is
expected to support the growth over the forecast period.
· The key diagnostic application areas of
radiopharmaceuticals formed the largest market in 2015. These applications are
in cardiology, neurology, oncology, and thyroid. Advent of accurate diagnostic
methods and high burden of disorders supported the growth of this segment.
· Thailand in South East Asia and China are
expected to dominate the APAC radiopharmaceutical market. Efforts undertaken by
the UN and other local healthcare authorities in this region are expected to
result in installation of more PET and SPECT systems, thereby driving the
demand.
· Key players of the industry include
Nordion, Inc., Bayer AG, Mallinckrodt Public Limited company, GE Healthcare,
Bracco Imaging S.P.A and government initiatives such as Institute of Radioisotopes
and The Australian Nuclear Science and Technology Organization (ANSTO)
Browse more reports of this category by Grand View
Research at: www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has
segmented the APAC radiopharmaceuticals market on the basis of product:
APAC Radiopharmaceuticals Product Outlook (Revenue, USD
Million, 2013 - 2024)
·
Diagnostics
·
Therapeutics
Radiopharmaceuticals Regional Outlook (Revenue, USD
Million, 2013 - 2024)
·
South East Asia
·
Rest of Asia Pacific
Access Press Release of
APAC Radiopharmaceuticals Market@ www.grandviewresearch.com/press-release/asia-pacific-radiopharmaceuticals-market-analysis
About
Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco.
The company provides syndicated research reports, customized research
reports, and consulting services. To help clients make informed business
decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
No comments:
Post a Comment